{
    "organizations": [],
    "uuid": "aead7f8c2f34df33a4daf01bbf42d2151b739029",
    "author": "",
    "url": "https://www.reuters.com/article/brief-aviragen-therapeutics-comments-on/brief-aviragen-therapeutics-comments-on-iss-report-idUSFWN1PL18X",
    "ord_in_thread": 0,
    "title": "BRIEF-Aviragen Therapeutics Comments on ISS Report",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 52 PM / in 17 minutes BRIEF-Aviragen Therapeutics Comments on ISS Report Reuters Staff 1 Min Read \nJan 26 (Reuters) - Aviragen Therapeutics Inc: \n* AVIRAGEN THERAPEUTICS - ISSUED STATEMENT IN RESPONSE TO REPORT BY INSTITUTIONAL SHAREHOLDER SERVICES REGARDING COâ€˜S PROPOSED MERGER WITH VAXART INC \n* AVIRAGEN THERAPEUTICS INC - AVIRAGEN BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE FOR PROPOSED MERGER WITH VAXART Source text for Eikon: Further company coverage:",
    "published": "2018-01-26T23:51:00.000+02:00",
    "crawled": "2018-01-27T00:04:07.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "therapeutic",
        "comment",
        "iss",
        "report",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "aviragen",
        "therapeutic",
        "inc",
        "aviragen",
        "therapeutic",
        "issued",
        "statement",
        "response",
        "report",
        "institutional",
        "shareholder",
        "service",
        "regarding",
        "co",
        "proposed",
        "merger",
        "vaxart",
        "inc",
        "aviragen",
        "therapeutic",
        "inc",
        "aviragen",
        "board",
        "director",
        "unanimously",
        "recommends",
        "stockholder",
        "vote",
        "proposed",
        "merger",
        "vaxart",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}